APOE and hyperhomocysteinemia: Likewise, in a model of hyperhomocysteinemia (HHcy)-accelerated plaques in apolipoprotein E-deficient (apoE–/–) mice abatacept-treatment reversed plaque development with reduced T cell-dependent macrophage recruitment and IFN-γ/Interleukin-2 secretion [51].